M&A Deal Summary |
|
|---|---|
| Date | 2024-04-23 |
| Target | Escient Pharmaceuticals |
| Sector | Life Science |
| Buyer(s) | Incyte |
| Deal Type | Add-on Acquisition |
| Advisor(s) | Centerview Partners Goldman Sachs (Financial) Fenwick & West (Legal) |
SEARCH BY
| Category | Company |
|---|---|
| Founded | 1991 |
| Sector | Life Science |
| Employees | 2,617 |
| Revenue | 4.2B USD (2024) |
Incyte is a biopharmaceutical company focused on the discovery, development and commercialization of proprietary therapeutics. Incyte was founded in 1991 and is based in Wilmington, Delaware.
| DEAL STATS | # |
|---|---|
| Overall | 5 of 5 |
| Sector: Life Science M&A | 4 of 4 |
| Type: Add-on Acquisition M&A Deals | 4 of 4 |
| State: California M&A | 2 of 2 |
| Country: United States M&A | 5 of 5 |
| Year: 2024 M&A | 1 of 1 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2022-10-03 |
Villaris
Cary, North Carolina, United States Villaris is an asset-centric biopharmaceutical company that developed a potentially transformational new treatment to improve the lives of people living with vitiligo. Villaris was formed in 2019 and is based in Cary, North Carolina. |
Buy | $1.4B |